Behind the Research: How Global Health Trials Are Run

Episode overview
"Behind the Research: How Global Health Trials Are Run" zooms out from any specific study to walk adults through the lifecycle of a rigorous trial in low‑resource settings.

Learning goals

• Demystify phases of a global‑health study: conception, funding, ethics, fieldwork, analysis, and dissemination.
• Highlight the roles of local partners and communities.
• Encourage more critical reading of press releases and headlines.

Segment 1 — From question to protocol

• Starting points: clinic observations, prior studies, or policy gaps.
• Turning a fuzzy concern into a precise, testable question.
• Writing a protocol that spells out inclusion criteria, endpoints, and analysis plans.

Segment 2 — Ethics and governance

• Local and international ethics review boards.
• Informed‑consent processes adapted to literacy and language contexts.
• Data‑safety monitoring boards for longer or higher‑risk studies.

Segment 3 — Fieldwork realities

• Training local staff; building capacity that remains after the trial.
• Logistics: cold chains, transport, power, data capture in remote sites.
• Handling disruptions: outbreaks, civil unrest, climate events.

Segment 4 — From data to decisions

• Pre‑registered analysis vs. exploratory digging.
• Interpreting effect sizes, cost‑effectiveness, and feasibility side by side.
• How null or negative results still matter for policy and science.

Segment 5 — Sharing back and moving forward

• Returning results to participating communities in accessible formats.
• Publishing in open‑access venues when possible.
• How findings feed into guideline committees, training curricula, and future grant applications.

Reflection prompts

• When you hear about a new trial in the news, what do you now want to know about its design and context?
• How might funders and institutions better reward “unflashy” but crucial work like capacity building and negative‑result publication?

Clinical trials are the backbone of medical progress, but how do they actually work—especially in resource-limited settings? This episode takes you behind the scenes of global health research to explore how trials are designed, conducted, and overseen across different countries and contexts. Whether you're curious about the ethics of international research, wondering how diverse populations are included in studies, or interested in the challenges researchers face in low-income countries, this episode reveals the complex reality of testing new treatments and interventions worldwide.

🔬 Understanding Clinical Trial Phases

Clinical trials progress through carefully structured phases, each designed to answer specific questions about safety and effectiveness:

• Phase I: Safety Testing - The first human trials with 20-80 participants focus on establishing a safe dosage range and identifying side effects. This phase answers the fundamental question: Is this treatment safe for humans?
• Phase II: Early Efficacy - With 100-300 participants, researchers begin to understand whether the treatment actually works while continuing to monitor safety. This phase determines if the treatment shows promise.
• Phase III: Broad Efficacy Testing - Large-scale trials with 1,000-3,000 participants confirm effectiveness, compare results with standard treatments, and prepare for regulatory approval. This is where the evidence builds for real-world use.
• Phase IV: Post-Approval Monitoring - After a treatment is approved, ongoing studies continue to monitor long-term effects in wider populations. This phase catches rare side effects and optimizes treatment protocols.

🌍 The Global Inequity Challenge

One of the most striking revelations about global health trials is the massive geographic disparity in where they take place:

• The Numbers Tell the Story - In 2022, there were 27,133 trials in the world's 86 high-income countries compared to just 24,791 in 131 low- and middle-income countries. This means approximately 83% of trials have been conducted in just 25 high-income countries, while less than 5% took place in 91 lower-middle or low-income countries—precisely where disease burden is often highest.
• Representation Gaps - Less than 5% of clinical trials include pregnant women, and only 13% include children. This means treatments are often approved without adequate testing in these populations, potentially missing important safety concerns or dosing adjustments.
• WHO's 2024 Guidance - In September 2024, the World Health Organization released landmark guidance to address these disparities—the first global guidance applicable to all clinical trials regardless of location or income level. This guidance emphasizes inclusivity, embedding research into health systems, and simplifying complex approval processes.

⚖️ Ethics and Informed Consent in Global Research

Conducting trials in diverse global settings raises complex ethical questions that researchers must navigate carefully:

• The Belmont Principles - Three foundational ethical principles guide all research: Respect (recognizing autonomy and requiring clear informed consent), Beneficence (ensuring research is beneficial and follows the Hippocratic ideal of 'do no harm'), and Justice (balancing benefits to society against risks to participants).
• Cultural Context Matters - Informed consent processes that work in Western contexts may not translate directly to settings where familial and physician-patient relationships are more hierarchical. Researchers must adapt consent processes while maintaining ethical standards, ensuring people truly understand what they're agreeing to participate in.
• Vulnerability and Exploitation - When trials are conducted with severely socio-economically disadvantaged populations, there's a heightened risk of undue influence. The very fact that participation in trials may be someone's only access to medical care creates ethical tensions that researchers must address through robust oversight and community engagement.
• Standard of Care Debates - Should trials in low-income countries use placebo controls when effective treatments exist in high-income countries? This question continues to generate debate, as researchers balance scientific rigor with ethical obligations to provide the best possible care to all participants.

🚧 Unique Challenges in Low-Income Settings

Running clinical trials in developing countries involves navigating a distinct set of obstacles that researchers in high-income settings rarely encounter:

• Financial and Human Resource Constraints - The majority of funding comes from Western countries or pharmaceutical companies, while local governments allocate minimal resources to research. There's a severe shortage of trained personnel, and those with skills often leave for better opportunities abroad—creating a 'brain drain' that perpetuates the capacity gap.
• Infrastructure Limitations - Limited testing facilities, unreliable electricity, inadequate cold chain storage for vaccines and biologics, and poor transportation networks all complicate trial logistics. Early-phase trials requiring sophisticated laboratory equipment are still largely conducted in high-income countries, though some Asian and African nations are beginning to develop these capabilities.
• Regulatory Hurdles - Complex and sometimes unreasonably strict government regulatory systems create unnecessary delays in ethical approval procedures. Studies frequently take significantly longer than expected to complete, with subject recruitment falling short of projections due to these barriers.
• Cultural and Social Factors - Religious beliefs and fear of exploitation in populations with memories of colonial medical abuse can hamper participation. Understanding local contexts, navigating logistical hurdles, and fostering partnerships with local stakeholders require meticulous planning that goes beyond standard clinical trial protocols.

🤝 Community Engagement and Participatory Research

One of the most important developments in global health research is the emphasis on meaningful community involvement throughout the research process:

• What It Means - Community Engagement and Involvement (CEI) means active participation of communities throughout the entire research process, from setting research agendas to disseminating results. It's not just about recruiting participants—it's about partnership and shared decision-making.
• Why It Matters - Better engagement improves the acceptability, feasibility, and relevance of trial design and implementation. It fosters trust in science, strengthens research literacy, and ensures that studies address questions that actually matter to the communities affected by the diseases being studied.
• Patient-Centered Approaches - WHO's 2024 guidance emphasizes putting patient, participant, and community engagement at the heart of clinical trials. This ensures that research planning, delivery, and dissemination meet public needs and maintain trust—critical in vulnerable populations with historical reasons for medical mistrust.

🎓 Building Research Capacity for the Future

Sustainable improvements in global health research depend on strengthening local capacity to design, conduct, and oversee trials:

• Training Programs - Organizations like TDR (Special Programme for Research and Training in Tropical Diseases) have trained over 7,300 researchers through MOOCs delivered in multiple languages, while programs like VIRDE (Vanderbilt Institute for Research Development and Ethics) provide intensive training in grant writing, research ethics, and career development tailored to LMIC contexts.
• Regional Networks - Initiatives like the INDOX Cancer Research Network partner universities in high-income countries with comprehensive cancer centers in India to enable local researchers to conduct trials to international standards. These partnerships create sustainable infrastructure that outlasts individual studies.
• Data Safety Monitoring - As trials in Africa and Asia expand, there's increasing need for Data Safety Monitoring Boards (DSMBs) with members who understand regional medical practices and regulatory environments. Training African scientists to serve on DSMBs ensures culturally and contextually relevant oversight of trials conducted in their regions.
• Sustainability Challenges - The main obstacles to sustained capacity building are lack of continuous funding (most comes from high-income countries, particularly the U.S. which funds 56% of initiatives), time constraints, inadequate mentoring, and limited attention to research methods in undergraduate and continuing education curricula.

🔄 International Collaboration and Data Sharing

Modern global health challenges require coordinated international research efforts:

• WHO's Registry Platform - The International Clinical Trials Registry Platform (ICTRP) links registries globally to ensure transparency and provide a single point of access for information. This helps prevent research duplication, identifies gaps in evidence, and enables patients and families to find relevant trials.
• Multi-Country Trials - Diseases don't respect borders, so trials shouldn't either. Platform trials that span multiple countries allow faster enrollment, greater diversity of participants, and the ability to adapt protocols as new evidence emerges—particularly valuable during pandemic responses.
• Funder Commitments - In September 2025, major medical research funders signed a joint statement committing to implement WHO standards for strengthening clinical trial systems. This represents a significant step toward more equitable and effective global health research.

📚 Sources & Learn More

WHO Resources & Clinical Trials Guidance

• WHO: New global guidance for more effective and equitable clinical trials
• WHO Clinical Trials Overview
• WHO Guidance for Best Practices for Clinical Trials (2024)
• WHO International Clinical Trials Registry Platform (ICTRP)
• Core funders commit to strengthening clinical trials worldwide

Ethics & Informed Consent

• The Ethical Implications of Clinical Trials in LMICs - American Bar Association
• The Ethics of Global Clinical Trials - BORGEN Magazine
• Research in Resource-Poor Countries - The Hastings Center

Challenges in Developing Countries

• Barriers to Conducting Clinical Trials in Developing Countries
• Dos and Don'ts when implementing RCTs in Developing Countries - Monash

Community Engagement

• Introduction to Community Engagement - Global Health Training Centre
• Community Engagement and Involvement - NIHR

Capacity Building & Training

• TDR: Strengthening Research Capacity
• Strengthening research capacity through intensive training (VIRDE) - BMC
• Data Safety and Monitoring Boards - Global Health Training Centre

Additional Resources

• ClinicalTrials.gov - U.S. Clinical Trials Database
• The Basics - NIH Clinical Research Trials